Loading…

MAFLD: How is it different from NAFLD?

"Metabolic dysfunction-associated fatty liver disease (MAFLD)" is the term suggested in 2020 to refer to fatty liver disease related to systemic metabolic dysregulation. The name change from nonalcoholic fatty liver disease (NAFLD) to MAFLD comes with a simple set of criteria to enable eas...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and molecular hepatology 2023, 29(0), , pp.17-31
Main Authors: Gofton, Cameron, Upendran, Yadhavan, Zheng, Ming-Hua, George, Jacob
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c484t-f61ed2d4056550fef2ecaa68c718dae035ed57ddc5b426611c0f9f718f430f063
cites cdi_FETCH-LOGICAL-c484t-f61ed2d4056550fef2ecaa68c718dae035ed57ddc5b426611c0f9f718f430f063
container_end_page S31
container_issue Suppl
container_start_page S17
container_title Clinical and molecular hepatology
container_volume 29
creator Gofton, Cameron
Upendran, Yadhavan
Zheng, Ming-Hua
George, Jacob
description "Metabolic dysfunction-associated fatty liver disease (MAFLD)" is the term suggested in 2020 to refer to fatty liver disease related to systemic metabolic dysregulation. The name change from nonalcoholic fatty liver disease (NAFLD) to MAFLD comes with a simple set of criteria to enable easy diagnosis at the bedside for the general medical community, including primary care physicians. Since the introduction of the term, there have been key areas in which the superiority of MAFLD over the traditional NAFLD terminology has been demonstrated, including for the risk of liver and extrahepatic mortality, disease associations, and for identifying high-risk individuals. Additionally, MAFLD has been adopted by a number of leading pan-national and national societies due to its concise diagnostic criterion, removal of the requirement to exclude concomitant liver diseases, and reduction in the stigma associated with this condition. The current article explores the differences between MAFLD and NAFLD diagnosis, areas of benefit, some potential limitations, and how the MAFLD terminology has opened up new fields of research.
doi_str_mv 10.3350/cmh.2022.0367
format article
fullrecord <record><control><sourceid>proquest_nrf_k</sourceid><recordid>TN_cdi_nrf_kci_oai_kci_go_kr_ARTI_10184876</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_550566d34434435f859cfe1bf0c5806e</doaj_id><sourcerecordid>3125511976</sourcerecordid><originalsourceid>FETCH-LOGICAL-c484t-f61ed2d4056550fef2ecaa68c718dae035ed57ddc5b426611c0f9f718f430f063</originalsourceid><addsrcrecordid>eNpVUU1LAzEUDKKoaI9eZUHwIGx9-dysFyl-tVAVRMFbSPOhW9tGs1vFf2-2tWJD4IXMvMm8DEIHGLqUcjg109cuAUK6QEWxgXYJkUVOJH_eXJ0LIndQp67HkFYBhJd0G-1QwRgtidhFx7e96-HlWdYPX1lVZ1WT2cp7F92syXwM0-yuxc_30ZbXk9p1fuseerq-erzo58P7m8FFb5gbJlmTe4GdJZYBF5yDd544o7WQpsDSageUO8sLaw0fMSIExgZ86RPoGQUPgu6hk6XuLHr1ZioVdLWoL0G9RdV7eBwoDFgyWbTkwZJsgx6r91hNdfxedCwuQnxROjaVmTiV3HAhLE1jp8295KXxDo88GC5BuKR1vtR6n4-mzpo0f9STNdF1ZFa9JlOfyQ2QsmRlUjj6VYjhY-7qRo3DPM7SbymKCecYlwvP-ZJlYqjr6PzfExhUm6lKmao2U9VmmviH_339sVcJ0h_yrJg_</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3125511976</pqid></control><display><type>article</type><title>MAFLD: How is it different from NAFLD?</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Gofton, Cameron ; Upendran, Yadhavan ; Zheng, Ming-Hua ; George, Jacob</creator><creatorcontrib>Gofton, Cameron ; Upendran, Yadhavan ; Zheng, Ming-Hua ; George, Jacob</creatorcontrib><description>"Metabolic dysfunction-associated fatty liver disease (MAFLD)" is the term suggested in 2020 to refer to fatty liver disease related to systemic metabolic dysregulation. The name change from nonalcoholic fatty liver disease (NAFLD) to MAFLD comes with a simple set of criteria to enable easy diagnosis at the bedside for the general medical community, including primary care physicians. Since the introduction of the term, there have been key areas in which the superiority of MAFLD over the traditional NAFLD terminology has been demonstrated, including for the risk of liver and extrahepatic mortality, disease associations, and for identifying high-risk individuals. Additionally, MAFLD has been adopted by a number of leading pan-national and national societies due to its concise diagnostic criterion, removal of the requirement to exclude concomitant liver diseases, and reduction in the stigma associated with this condition. The current article explores the differences between MAFLD and NAFLD diagnosis, areas of benefit, some potential limitations, and how the MAFLD terminology has opened up new fields of research.</description><identifier>ISSN: 2287-2728</identifier><identifier>EISSN: 2287-285X</identifier><identifier>DOI: 10.3350/cmh.2022.0367</identifier><identifier>PMID: 36443926</identifier><language>eng</language><publisher>Korea (South): Korean Association for the Study of the Liver</publisher><subject>Alcohol use ; Gastroenterology ; High density lipoprotein ; Humans ; Liver cirrhosis ; Liver diseases ; mafld ; mafld vs. nafld ; Metabolic Diseases - classification ; Metabolic Diseases - diagnosis ; Metabolism ; nafld ; Name changes ; Non-alcoholic Fatty Liver Disease - classification ; Non-alcoholic Fatty Liver Disease - diagnosis ; Overweight ; Patients ; Perceptions ; Review ; Risk factors ; Terminology ; 내과학</subject><ispartof>Clinical and Molecular Hepatology, 2023, 29(0), , pp.17-31</ispartof><rights>2023. This work is published under http://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2023 by The Korean Association for the Study of the Liver 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c484t-f61ed2d4056550fef2ecaa68c718dae035ed57ddc5b426611c0f9f718f430f063</citedby><cites>FETCH-LOGICAL-c484t-f61ed2d4056550fef2ecaa68c718dae035ed57ddc5b426611c0f9f718f430f063</cites><orcidid>0000-0002-0913-7180</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10029949/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/3125511976?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,313,314,727,780,784,792,885,25753,27922,27924,27925,37012,44590,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36443926$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002933075$$DAccess content in National Research Foundation of Korea (NRF)$$Hfree_for_read</backlink></links><search><creatorcontrib>Gofton, Cameron</creatorcontrib><creatorcontrib>Upendran, Yadhavan</creatorcontrib><creatorcontrib>Zheng, Ming-Hua</creatorcontrib><creatorcontrib>George, Jacob</creatorcontrib><title>MAFLD: How is it different from NAFLD?</title><title>Clinical and molecular hepatology</title><addtitle>Clin Mol Hepatol</addtitle><description>"Metabolic dysfunction-associated fatty liver disease (MAFLD)" is the term suggested in 2020 to refer to fatty liver disease related to systemic metabolic dysregulation. The name change from nonalcoholic fatty liver disease (NAFLD) to MAFLD comes with a simple set of criteria to enable easy diagnosis at the bedside for the general medical community, including primary care physicians. Since the introduction of the term, there have been key areas in which the superiority of MAFLD over the traditional NAFLD terminology has been demonstrated, including for the risk of liver and extrahepatic mortality, disease associations, and for identifying high-risk individuals. Additionally, MAFLD has been adopted by a number of leading pan-national and national societies due to its concise diagnostic criterion, removal of the requirement to exclude concomitant liver diseases, and reduction in the stigma associated with this condition. The current article explores the differences between MAFLD and NAFLD diagnosis, areas of benefit, some potential limitations, and how the MAFLD terminology has opened up new fields of research.</description><subject>Alcohol use</subject><subject>Gastroenterology</subject><subject>High density lipoprotein</subject><subject>Humans</subject><subject>Liver cirrhosis</subject><subject>Liver diseases</subject><subject>mafld</subject><subject>mafld vs. nafld</subject><subject>Metabolic Diseases - classification</subject><subject>Metabolic Diseases - diagnosis</subject><subject>Metabolism</subject><subject>nafld</subject><subject>Name changes</subject><subject>Non-alcoholic Fatty Liver Disease - classification</subject><subject>Non-alcoholic Fatty Liver Disease - diagnosis</subject><subject>Overweight</subject><subject>Patients</subject><subject>Perceptions</subject><subject>Review</subject><subject>Risk factors</subject><subject>Terminology</subject><subject>내과학</subject><issn>2287-2728</issn><issn>2287-285X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpVUU1LAzEUDKKoaI9eZUHwIGx9-dysFyl-tVAVRMFbSPOhW9tGs1vFf2-2tWJD4IXMvMm8DEIHGLqUcjg109cuAUK6QEWxgXYJkUVOJH_eXJ0LIndQp67HkFYBhJd0G-1QwRgtidhFx7e96-HlWdYPX1lVZ1WT2cp7F92syXwM0-yuxc_30ZbXk9p1fuseerq-erzo58P7m8FFb5gbJlmTe4GdJZYBF5yDd544o7WQpsDSageUO8sLaw0fMSIExgZ86RPoGQUPgu6hk6XuLHr1ZioVdLWoL0G9RdV7eBwoDFgyWbTkwZJsgx6r91hNdfxedCwuQnxROjaVmTiV3HAhLE1jp8295KXxDo88GC5BuKR1vtR6n4-mzpo0f9STNdF1ZFa9JlOfyQ2QsmRlUjj6VYjhY-7qRo3DPM7SbymKCecYlwvP-ZJlYqjr6PzfExhUm6lKmao2U9VmmviH_339sVcJ0h_yrJg_</recordid><startdate>20230201</startdate><enddate>20230201</enddate><creator>Gofton, Cameron</creator><creator>Upendran, Yadhavan</creator><creator>Zheng, Ming-Hua</creator><creator>George, Jacob</creator><general>Korean Association for the Study of the Liver</general><general>The Korean Association for the Study of the Liver</general><general>대한간학회</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope><scope>DOA</scope><scope>ACYCR</scope><orcidid>https://orcid.org/0000-0002-0913-7180</orcidid></search><sort><creationdate>20230201</creationdate><title>MAFLD: How is it different from NAFLD?</title><author>Gofton, Cameron ; Upendran, Yadhavan ; Zheng, Ming-Hua ; George, Jacob</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c484t-f61ed2d4056550fef2ecaa68c718dae035ed57ddc5b426611c0f9f718f430f063</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Alcohol use</topic><topic>Gastroenterology</topic><topic>High density lipoprotein</topic><topic>Humans</topic><topic>Liver cirrhosis</topic><topic>Liver diseases</topic><topic>mafld</topic><topic>mafld vs. nafld</topic><topic>Metabolic Diseases - classification</topic><topic>Metabolic Diseases - diagnosis</topic><topic>Metabolism</topic><topic>nafld</topic><topic>Name changes</topic><topic>Non-alcoholic Fatty Liver Disease - classification</topic><topic>Non-alcoholic Fatty Liver Disease - diagnosis</topic><topic>Overweight</topic><topic>Patients</topic><topic>Perceptions</topic><topic>Review</topic><topic>Risk factors</topic><topic>Terminology</topic><topic>내과학</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gofton, Cameron</creatorcontrib><creatorcontrib>Upendran, Yadhavan</creatorcontrib><creatorcontrib>Zheng, Ming-Hua</creatorcontrib><creatorcontrib>George, Jacob</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals(OpenAccess)</collection><collection>Korean Citation Index</collection><jtitle>Clinical and molecular hepatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gofton, Cameron</au><au>Upendran, Yadhavan</au><au>Zheng, Ming-Hua</au><au>George, Jacob</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>MAFLD: How is it different from NAFLD?</atitle><jtitle>Clinical and molecular hepatology</jtitle><addtitle>Clin Mol Hepatol</addtitle><date>2023-02-01</date><risdate>2023</risdate><volume>29</volume><issue>Suppl</issue><spage>S17</spage><epage>S31</epage><pages>S17-S31</pages><issn>2287-2728</issn><eissn>2287-285X</eissn><abstract>"Metabolic dysfunction-associated fatty liver disease (MAFLD)" is the term suggested in 2020 to refer to fatty liver disease related to systemic metabolic dysregulation. The name change from nonalcoholic fatty liver disease (NAFLD) to MAFLD comes with a simple set of criteria to enable easy diagnosis at the bedside for the general medical community, including primary care physicians. Since the introduction of the term, there have been key areas in which the superiority of MAFLD over the traditional NAFLD terminology has been demonstrated, including for the risk of liver and extrahepatic mortality, disease associations, and for identifying high-risk individuals. Additionally, MAFLD has been adopted by a number of leading pan-national and national societies due to its concise diagnostic criterion, removal of the requirement to exclude concomitant liver diseases, and reduction in the stigma associated with this condition. The current article explores the differences between MAFLD and NAFLD diagnosis, areas of benefit, some potential limitations, and how the MAFLD terminology has opened up new fields of research.</abstract><cop>Korea (South)</cop><pub>Korean Association for the Study of the Liver</pub><pmid>36443926</pmid><doi>10.3350/cmh.2022.0367</doi><tpages>15</tpages><orcidid>https://orcid.org/0000-0002-0913-7180</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2287-2728
ispartof Clinical and Molecular Hepatology, 2023, 29(0), , pp.17-31
issn 2287-2728
2287-285X
language eng
recordid cdi_nrf_kci_oai_kci_go_kr_ARTI_10184876
source Publicly Available Content Database; PubMed Central
subjects Alcohol use
Gastroenterology
High density lipoprotein
Humans
Liver cirrhosis
Liver diseases
mafld
mafld vs. nafld
Metabolic Diseases - classification
Metabolic Diseases - diagnosis
Metabolism
nafld
Name changes
Non-alcoholic Fatty Liver Disease - classification
Non-alcoholic Fatty Liver Disease - diagnosis
Overweight
Patients
Perceptions
Review
Risk factors
Terminology
내과학
title MAFLD: How is it different from NAFLD?
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T19%3A40%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_nrf_k&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=MAFLD:%20How%20is%20it%20different%20from%20NAFLD?&rft.jtitle=Clinical%20and%20molecular%20hepatology&rft.au=Gofton,%20Cameron&rft.date=2023-02-01&rft.volume=29&rft.issue=Suppl&rft.spage=S17&rft.epage=S31&rft.pages=S17-S31&rft.issn=2287-2728&rft.eissn=2287-285X&rft_id=info:doi/10.3350/cmh.2022.0367&rft_dat=%3Cproquest_nrf_k%3E3125511976%3C/proquest_nrf_k%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c484t-f61ed2d4056550fef2ecaa68c718dae035ed57ddc5b426611c0f9f718f430f063%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3125511976&rft_id=info:pmid/36443926&rfr_iscdi=true